Trial Profile
Efficacy of Erlotinib as salvage treatment in patients with pulmonary adenocarcinoma with disease progression after previous EGFR-TKI treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2017
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Aug 2017 New trial record